BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/13/2016 9:14:00 AM | Browse: 295 | Download: 388
Publication Name World Journal of Gastroenterology
Manuscript ID 25292
Country of Manuscript Source China
Received
2016-03-05 13:21
Peer-Review Started
2016-03-07 09:05
To Make the First Decision
2016-03-21 09:32
Return for Revision
2016-03-22 10:10
Revised
2016-03-31 17:09
Second Decision
2016-04-13 07:57
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2016-04-20 14:20
Articles in Press
2016-04-20 14:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
2016-05-25 08:14
Typeset the Manuscript
2016-06-02 08:45
Publish the Manuscript Online
2016-06-13 09:14
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Case Control Study
Article Title Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients
Manuscript Source Unsolicited Manuscript
All Author List Feng Xia, Li-Li Wu, Wan-Yee Lau, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li and Ping Bie
Funding Agency and Grant Number
Funding Agency Grant Number
Key Laboratory of Tumor Immunology and Pathology of Ministry of Education 2012jsz108
National Natural Sciences Foundation of China 81272224
Correspondence To Feng Xia, MD, PhD, Professor of Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, No. 30 Gaotanyanzhengjie, Chongqing 400038, China. txzzxf@163.com
Keywords Hepatectomy; Hepatocellular carcinoma; Sorafenib; Survival; Tumor recurrence
Core Tip Hepatocellular carcinoma (HCC) has a 5-year recurrence rate reaching 80%-90% even after potentially curative treatment. Therefore, it is extremely important to prevent recurrence for the prognosis of HCC patients. Sorafenib is the only approved treatment for patients with advanced HCC. Thus, based on the action of sorafenib, namely inhibition of tumor cell proliferation and angiogenesis, there is rationale for the study of sorafenib as an adjuvant therapy in HCC. It is essential to investigate the efficacy and safety of adjuvant sorafenib administered following curative resection in patients with Barcelona Clinic Liver Cancer-stage C HCC.
Publish Date 2016-06-13 09:14
Citation Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016; 22(23): 5384-5392
Url http://www.wjgnet.com/1007-9327/full/v22/i23/5384.htm
DOI http://dx.doi.org/10.3748/wjg.v22.i23.5384
Full Article (PDF) WJG-22-5384.pdf
Full Article (Word) WJG-22-5384.doc
Revised Manuscript 25292-Review.doc
Peer-review Report 25292-Peer-review(s).pdf
Answering Reviewers 25292-Answering reviewers.pdf
Scientific Misconduct Check 25292-Scientific misconduct check.pdf
Scientific Editor Work List 25292-Scientific editor work list.pdf
Audio Core Tip 25292-Audio core tip.MP3
Copyright License Agreement 25292-Copyright assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 25292-Grant application form(s).pdf
Institutional Review Board Approval Form or Document 25292-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 25292-Language certificate.pdf